Clinical Trials Browser

Recurrence × daratumumab × Plasma cell × Clear all

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

440 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05455320 2026-01-16

MonumenTAL-3

Phase 3 Active not recruiting

864 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04824794 2025-12-22

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Phase 1/2 Terminated

130 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT06827860 2025-12-18

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Phase 2 Recruiting

23 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase 2 Recruiting

43 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

19 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03836014 2024-12-06

CONFIRM

Phase 3 Active not recruiting

436 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1/2 Active not recruiting

424 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02773030 2024-06-25

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Phase 1/2 Active not recruiting

466 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03450057 2024-03-29

DARE

Phase 2 Completed

38 enrolled 16 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT04136756 2023-06-15

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Phase 1 Completed

30 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1 Terminated

8 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT03651128 2022-12-15

KarMMa-3

Phase 3 Active not recruiting

381 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03000452 2018-10-16

FUSION-MM-005

Phase 2 Completed

18 enrolled 16 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT03143036 2018-06-07

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Phase 2 Unknown

100 enrolled

Plasma cell

Recurrence, Neoplasms, Plasma Cell

NCT02116569 2016-09-26

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

9 enrolled

Plasma cell

Multiple Myeloma, Recurrence